Sold out

Daylon Pharma Products

Zrepag

In Post prandial hyperglycemia in Type 2 Diabetes
RxZrepag contains Repaglinide0.5/1/2mg

”Reduces CVD Risk in Diabeticswith Dyslipidemia.”

With ZrepagMore percentage of patients achieved glucose peak vs. Glyburide

Description

In Post prandial hyperglycemia in Type 2 Diabetes

RxZrepag contains  Repaglinide0.5/1/2mg

”Reduces CVD Risk in Diabeticswith Dyslipidemia.”

With ZrepagMore percentage of patients achieved glucose peak  vs. Glyburide

Explain the chart

Repaglinide

ZrepagReduces inflammatory markers

• C-reactive protein decrease more in Repaglinide group vs. Glyburide group
• 52% patients showed (>0.020mm) decrease in carotid intima-media thickness

Back

Doctor…

Metformin

• ZrepagIncreases peripheral insulin sensitivity
• ZrepagReduces hepatic glucose production

Voglibose

• Delays digestion and absorption of sugar
• Improves post prandial hyperglycemia
• Lesser GI side effects vs. Acarbose

Our Zrepag range of products available:

Zrepag 0.5 /1/2MG Contains  Repaglinide 0.5/1/2mg 

ZrepagMF Contains  Repaglinide 0.5/1/2 mg + Metformin 500 mg  

Zrepag Rapid Contains Repaglinide 0.5/1 mg + Voglibose 0.3mg ) 

Thus Doctor  In Post prandial hyperglycemia in Type 2 Diabetes

RxZrepagRange Which ”Reduces CVD Risk in Diabeticswith Dyslipidemia.”

Lookingforward for yourprescriptions.